Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

- PMLiVE

GSK gets another approval for Nucala in US

Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

Bayer symbol

Bayer gets clinical data to support $1.5bn Loxo deal

Larotrectinib’s response rate likely to be practice changing

Bayer symbol

Joerg Moeller to head Bayer R&D after operational shake-up

Andreas Busch to move to Shire as head of R&D and CSO

AstraZeneca AZ

AZ speeds first-line lung cancer filing for Tagrisso to EMA

As FLAURA trial results show boosted progression-free survival

- PMLiVE

Regeneron and Bayer drop AMD combination

Abandon plans after disappointing phase II trial results

Bayer symbol

Bayer drug-device combo for pneumonia flunks phase III test

NKTR-061 failed to provide additional benefit over standard antibiotic treatment

- PMLiVE

Bayer picks up PMEA award for multi-channel engagement

Close-run category sees its iMCM Lighthouse Project triumph

- PMLiVE

Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

The German pharma group will gain full rights to the drugs outside the US

AstraZeneca AZ

AZ CEO says company’s renaissance is on track

Soriot insists AZ’s strategy is working and will continue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links